
RESULTS FOR HALF-YEAR TO 31 DEC 2025

Highlights

- Revenue increased 53% to \$8M (1H FY25: \$5.27M)
 - 1H FY26 Normalised EBITDA of \$1.6M at 20% operating margin
 - Profit after tax of \$1.5 million (1H FY25: \$1.0 million loss)
 - Positive operating cashflow
 - Major global pharma clinical trial execution progressing as planned
 - TrialsWest clinic network expansion progressing ahead of expectations
 - SaMD order and bid pipeline now above \$10 million
 - New Non-Invasive Liver Fibrosis medical device extended-proof-of-concept-trial (EPoC) completed subject enrolment
 - New “Bridge” technology that automates and simplifies customer interaction has completed testing and validation with first customer deployment underway
 - Cash at bank of \$2.7M at half-year-end matching bank debt of \$2.7M
-

Resonance Health Delivers Record Revenue Growth and Returns to Profit in 1H FY26

Resonance Health Limited (ASX: RHT) (“Resonance” or “Company”) is pleased to release its Appendix 4D and Half-Year Financial Report for the six-months ended 31 December 2025, reporting continued strong revenue growth and a return to profitability.

Financial Performance

Revenue increased 53% to \$8M (1H FY25: \$5.27M), driven by continued execution across all three business units:

- **\$4.4M** in revenue recognised in Resonance Clinical from the continued delivery of the clinical trial service agreements with global major- pharmaceutical companies
- TrialsWest clinical site network performed above expectations
- Increased commercial and clinical-trial volumes in the software-as-a-medical-device (SaMD) business across FerriScan® and HepaFat®, alongside the introduction of additional devices including Magnetic Resonance Elastography (MRE) and Visceral and Subcutaneous Adipose Tissue (VAT & SAT) measurement

The Company recorded net profit after tax of \$1.5M, and the business continued generating net positive operating cashflow.

Operational Update

Resonance Health continues to execute across its three business focus areas:

1. **Clinical Trial Management (CRO) Services (Resonance Clinical)**
2. **Clinical Trial Site Services (TrialsWest)**
3. **Software-as-a-Medical Device (SaMD) Image Analysis Services**

Resonance Clinical

The Company progressed the \$13.8M global major -pharma clinical trial services agreement announced in November 2024 during the period with enrolment on this trial expected to complete during Q3 FY26.

The final clinical study report for the global major-pharma clinical trial services agreement announced in August 2023 was finalised during the period and issued to the customer, successfully concluding that service delivery engagement.

Resonance Clinical has a significant bid pipeline as it continues to pursue new clinical trial service engagement opportunities with both existing and new customers, with some potential opportunities denominated in values similar to previously awarded trials.

TrialsWest

TrialsWest continued to expand its patient reach and clinical trial service capability during the half-year, underpinned by demand from global major-pharmaceutical sponsors:

- The Osborne Park WA clinic exceeded expectations, achieving monthly profitability and a projected annualised revenue run-rate currently exceeding \$2M
- The Mandurah WA clinic is approaching breakeven ahead of schedule with several new clinical trials coming online imminently

The Company continues to evaluate further clinical trial site expansion opportunities and therapeutic area expansion particularly in metabolic / endocrine and oncology.

Software-as-a-Medical Device (SaMD)

The SaMD business secured new clinical trial service contracts and extensions of existing service contracts with global pharmaceutical customers. Total forward order and tendered pipeline now exceed **\$10M**. If successful, these service agreements would be delivered over multi-year contract terms.

During the period, the Company also:

- Completed testing and validation of its new **“Bridge” automation technology**, with first customer deployment underway
- Completed enrolment in the extended proof-of-concept (EPoC) trial for its non-invasive MRI Liver Fibrosis SaMD

A regulatory plan is currently being developed setting out key clinical and regulatory milestones as we consider global regulatory clearances for the liver fibrosis device, subject to the successful outcome of the EPoC.

In addition, the Company is progressing discussions with healthcare providers in China with a view to providing Resonance Health services in that high-volume market.

Further, as a result of its recent work with Indian based global pharmaceutical companies and a successful business development visit to India, the Company has identified opportunities with new and existing customers in that market. In response to the scale of the opportunity in that market, Resonance Health has appointed a dedicated Business Development Manager in India to further develop these opportunities.

Resonance Health's CEO & Managing Director, Mr Andrew Harrison said:

"1H FY26 represents a strong period of execution across the Group. We delivered material revenue growth, returned to profitability, and continued to expand each of our three operating divisions.

With strong bid activity across SaMD and Resonance Clinical, additional sites and expanding patient capacity in TrialsWest, and important development milestones approaching, the Company remains focused on disciplined growth and operational delivery."

Outlook & Guidance

Resonance enters 2H FY26 with:

- Continued delivery under global major pharmaceutical agreements
- Record SaMD forward orders and bid-tender pipeline
- Expanding and increasingly profitable TrialsWest operations
- Near-term milestones in fibrosis SaMD development and workflow automation

Previously stated guidance of full year FY26 Revenue of \$17M and EBITDA of \$2M is maintained.

The Board remains confident in the Company's strategy to scale its integrated healthcare technology and clinical services platform.

To watch Mr Harrison's video presentation, please visit the Company's InvestorHub:

<https://investors.resonancehealth.com/link/PRQ2kr>

Further Information

<https://investors.resonancehealth.com>

This announcement has been authorised for release in accordance with the delegated authority of the Board of Directors of Resonance Health Limited.

For further information:

Andrew Harrison

Managing Director

E: andrewh@resonancehealth.com

P: +61 8 9286 5300

About Resonance Health

Resonance Health is an Australian healthcare technology and services company. The Company's services are used globally by clinicians in the management of human diseases and by pharmaceutical and therapeutic companies in their clinical trials. Resonance Health has gained endorsement by leading physicians worldwide for providing high quality quantitative assessments essential in managing diseases and drug development.

Resonance Health's dedication to scientific rigour and quality has enabled it to achieve regulatory clearances for a range of Software-as-Medical Devices (**SaMDs**) in the USA, Europe, UK, and Australia, and to proudly carry ISO 13485 certification for the design and manufacture of medical devices. Regulatory cleared SaMD products, some of which incorporate Artificial Intelligence (**AI**), include:

- **FerriScan**[®], a core-lab product that provides an accurate assessment of liver iron concentration (**LIC**) through non-invasive MRI-based technology, for use in the assessment of individuals with iron overload conditions. Internationally recognised as the gold standard in LIC assessment.
- **FerriSmart**[®], an AI-trained, non-invasive MRI-based device for the automated real-time assessment of LIC in participants, calibrated against the global gold standard, FerriScan[®].
- **HepaFatScan**[®], an MRI-based solution providing a reliable non-invasive assessment of liver-fat in liver tissue for use in the assessment of individuals with confirmed or suspected fatty-liver-disease.
- **HepaFatSmart**, an AI-trained, non-invasive device for automated multi-metric assessment of liver-fat in participants, for the assessment of individuals with confirmed or suspected fatty liver disease.
- **LiverSmart**[®], an AI-trained, non-invasive MRI-based multi-parametric device combining FerriSmart[®] and HepaFat-AI[®] into a consolidated report providing accurate assessment of LIC and liver fat.
- **CardiacT2***, the most widely accepted MRI method for assessing heart iron loading. Resonance Health offers a dual analysis of FerriScan[®] and CardiacT2*.

The Company has a development pipeline of additional medical imaging analysis products and services, including the **MRI Liver Fibrosis Project**, aimed at accurately assessing the presence and progression of liver fibrosis utilising non-invasive MRI analysis. The Company also has a clinical trials business which both manages clinical trials in Australia and includes the site management operations of TrialsWest.

Stakeholders, including clinicians, participants, and shareholders, are encouraged to register their interest at www.resonancehealth.com and to follow Resonance Health on LinkedIn.

Disclaimer Forward Looking Statements

This presentation has been prepared by Resonance Health Ltd ("Resonance Health" or "Company") and may contain forward-looking statements that are based on current expectations and beliefs and are subject to numerous factors and uncertainties that could cause actual results to differ materially from those described. Forward looking statements contained in this release may include statements about future financial and operating results, status of regulatory submissions, possible or assumed future growth opportunities and risks and uncertainties that could affect Resonance Health's products and services.

These forward-looking statements are not guarantees of future performance, involve certain risks, uncertainties and assumptions that are difficult to predict, and are based upon assumptions as to future events that may prove inaccurate. Actual outcomes and results may differ materially from what is expressed in any forward-looking statement in which Resonance Health expresses an expectation or belief as to future results. There can be no assurance that the statement or expectation or belief will result or be achieved or accomplished. Resonance Health will not update forward-looking statements unless required by law.